Vaxcyte, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $794.3M | $476.6M | $332.3M | $169.5M | $78.4M |
| Operating expenses | $923.7M | $569.5M | $468.0M | $232.3M | $103.7M |
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M |
| Interest expense | — | $0 | $0 | $2,000 | $7,000 |
| Income tax expense | $0 | $0 | $0 | — | — |
| Net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M |
| Balance Sheet | |||||
| Cash and equivalents | $174.0M | $387.9M | $397.5M | $834.7M | $69.0M |
| Current assets | $1.6B | $1.8B | $1.1B | $942.6M | $256.3M |
| Total assets | $3.0B | $3.5B | $1.4B | $1.0B | $324.3M |
| Current liabilities | $205.8M | $140.2M | $145.3M | $40.5M | $28.7M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M |
| Stockholders' equity | $2.7B | $3.3B | $1.2B | $953.6M | $284.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M |
| Depreciation and amortization | $16.4M | $7.0M | $3.2M | $2.8M | $1.8M |
| Stock-based compensation | $138.8M | $84.8M | $48.8M | $23.6M | $10.7M |
| Capital expenditure | $13.7M | $22.4M | $16.1M | $5.8M | $6.6M |
| Free cash flow | -$669.3M | -$475.1M | -$312.9M | -$176.4M | -$127.9M |
| Impairments | — | $0 | $0 | $200,000 | $0 |
Shares outstanding 144.4M · Free float 94.8%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.